MP47-11 EXTENDED PELVIC LYMPH NODE DISSECTION FOR INTERMEDIATE-HIGH RISK PROSTATE CANCER: FREQUENCY AND DISTRIBUTION OF NODAL METASTASES.
Marco Roscigno*, Maria Nicolai, Richard LJ Naspro, Federico Pellucchi, Laura B Cornaghi, Daniela Chinaglia, Antonino Sacc a, Luigi F Da Pozzo, Bergamo, Italy INTRODUCTION AND OBJECTIVES: Standard extended pelvic lymph node dissection (ePLND) included the removal of external iliac, obturator and internal iliac chains. However, mapping studies demostrated that extending template up to the ureteric crossing would remove approximately 75% of all primary landing sites, and suggested to add presacral node dissection to ePLND, in order to correctly remove nodal metastases in 97% of patients. The aim of this study is to describe the frequency and distribution of metastases to pelvic nodes, in patients (Pts) with clinically localised, intermediate-high risk prostate cancer (PCa) according to the EAU guidelines, treated with radical prostatectomy and ePLND.
METHODS: We retrospectively evaluated 554 consecutive Pts with clinically localized, intermediate-high risk PCa, treated with open radical prostatectomy and ePLND between 2009 and 2015 at a single institution by multiple experienced surgeons. The ePLND always consisted of the external iliac, obturator, internal iliac, presacral and common iliac nodal site up to the ureteric crossing. Specimens from each anatomic site were sent in separate packets.
RESULTS: The median number of removed nodes was 22 (range 9-61). Positive nodes (LNþ) were found in 119 patients (21.4%). The mean and median number of positive nodes were 2.9 and 1 (range: 1-18), respectively. The median number of removed nodes was 6, 8, 5, 2, and 1 for external iliac, obturator, internal iliac, common iliac, and presacral site, respectively. Out of the 119 Pts, nodal metastases were found in 54 (45.4%), 50 (42%), 56 (47.1%), 12 (10.1%) and 15 (12.6%) in the external iliac, obturator, internal iliac, common iliac, and presacral sites, respectively. However, when analyzing the presence of positive nodes only in a single anatomic area, nodal metastases were present in 19 (16%), 18 (15.1%), 25 (21%), 0, and 3 (2%) in the external iliac, obturator, internal iliac, common iliac, and presacral site, respectively. A limited LND would have correctly staged 92 (77%) Pts and would have removed all LNþ in 37 (31%) Pts. An extended LND would have correctly staged 116 (97%) Pts but removed all LNþ in only 93 (78%) Pts.
CONCLUSIONS: Internal iliac and presacral nodes harbored metastases in more than 60% of cases, and positive nodes were present only in these areas in 23% of cases. On the contrary, metastases at common iliac nodes were always associated with concomitant involvement of external iliac, obturator and/or internal iliac nodes. An extended LND would have correctly staged 116 (97%) Pts but removed all LNþ in only 93 (78%) Pts.
Source of Funding: None

MP47-12 IMPACT OF PROXIMITY TO NCI-AND NCCN-DESIGNATED CANCER CENTERS ON OUTCOMES FOR PATIENTS WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
Cameron Ghaffary*, Galveston, TX; Zhigang Duan, Brian Chapin, Houston, TX; Tamer Dafashy, Christopher Kosareck, Galveston, TX; Karim Chamie, los angeles, CA; Simon Kim, Clevland, OH; Thomas Ahlering, Irvine, CA; John Davis, Sharon Giordano, Houston, TX; Stephen Williams, Galveston, TX INTRODUCTION AND OBJECTIVES: National Cancer Institute (NCI) and National Comprehensive Cancer Network (NCCN)-designated cancer centers (CCs) offer patients state-of-the-art treatment. We sought to identify whether proximity to NCI/NCCN CCs was associated with survival outcomes for prostate cancer patients who undergo radical prostatectomy (RP).
METHODS: A total of 12,478 total patients diagnosed with clinical stage T1 or T2 prostate cancer between 2004e2011 using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data were included. Multivariable regression analyses were used to quantify overall survival and use of secondary therapies for RP patients according to proximity to NCI/NCCN CCs. Cox proportional hazards models were used to quantify the association between survival outcomes and access to NCI/NCCN CCs RESULTS: Patients with proximity to ¼2 NCI centers and those diagnosed in 2011 enjoyed a statistically significant overall INTRODUCTION AND OBJECTIVES: High-dose-rate brachytherapy (HDR) with external-beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) and radical prostatectomy (RP) are common treatment options for high-risk prostate cancer (PC). We retrospectively evaluated the mid-term outcomes of both treatment groups and compared the rates of biochemical recurrence (BCR) and clinical progression-free survival (CPFS).
METHODS: Between 2004 and 2014, 589 patients with highrisk PC underwent RP (n ¼ 302) or HDR (n ¼ 287). RP included extended lymph node dissection. HDR was performed with EBRT and/ or neoadjuvant and long-term adjuvant ADT. The definition of BCR for each treatment was different, namely prostate specific antigen (PSA) level 0.2 ng/mL for RP and PSA nadir plus 2 (Phoenix definition) for HDR. Kaplan-Meier analyses and multivariable Cox regression analyses were performed to predict BCR and CPFS.
RESULTS: The median follow-up times of RP and HDR were 49 and 52 months, respectively. Patients who underwent HDR were significantly older (P < 0.001), had higher mean initial PSA levels (P < 0.001), higher clinical T stage (P ¼ 0.093), and higher mean biopsy Gleason score (P < 0.001). Five-year BCR free survival was significantly better after HDR than RP (80.1% vs. 62.9%; P < 0.001). However, there was no significant difference in the 5-year CPFS between HDR and RP groups (88.9% vs. 91.8%; P ¼ 0.68). After RP, 64.6% (195/302) of patients required no additional treatment. In multivariate analysis, clinical T stage (P < 0.01) and biopsy Gleason score (P < 0.01), but not modality (P¼0.749), were significant predictive factors of CP.
CONCLUSIONS: In this 10-year investigation at our institute, patients who underwent HDR had worse pre-treatment characteristics; however, had better BCR-free survival than patients who underwent RP. However, CPFS was not significantly different between patients who underwent either of the treatments. (PCa) patients that were primarily treated with radical prostatectomy (RP) and harboured aggressive disease (i.e. upgrading/upstaging). However, it remains unclear if the same phenomenon can be observed, when contemporary risk stratification tools, namely preoperative CAPRA relative to postoperative CAPRA-S risk-scores at RP, are used.
METHODS: We evaluated 17,251 PCa patients treated with radical prostatectomy and pelvic lymph node dissection at two European tertiary care referral centres between 1991 and 2016. All patients were stratified into low(LR)-, intermediate(IR)-and high-risk(HR) according to pre-and postoperative CAPRA risk-scores (2, 3-5 and 6 points, respectively). Multivariable cox regression models were fitted to
